Significant clinical added value in the management of patients with cryopyrin-associated periodic syndromes
KINERET, an interleukin-1 antagonist for daily injection, has Marketing Authorisation in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in patients from the age of 8 months, including: Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS).
It has been shown to be effective in reducing the intensity of symptoms in the most serious form of CAPS (the CINCA form) during a study with methodological limitations.
Clinical Benefit
Substantial
In the indication : Cryopyrin-Associated Periodic Syndromes (CAPS). Substantial
Low
In the indication : rheumatoid arthritis in combination with methotrexate Low
Clinical Added Value
important
In the indication: Cryopyrin-Associated Periodic Syndromes (CAPS) Given its demonstrated efficiency in severe forms of cryopyrinopathies (CINCA syndrome/NOMID) despite the methodological limitations of the studies available, its ability to cross the blood-brain barrier, the absence of any available alternative treatment in patients aged under 2 years and despite the need for daily injections, KINERET, like ILARIS, provides significant improvement in actual benefit (level II) in the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults, adolescents, children and babies aged 8 months or older with a body weight of 10 kg or above.
no clinical added value
In the indication : rheumatoid arthritis in combination with methotrexate These proprietary medicinal products are additions to the range that do not provide an improvement in actual benefit (level V) in comparison with the other previously registered presentations.
Listen
